UNSPSC 51271920: Piridocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C14H20N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VG6P406YHV. Most nations, for tariff and trade purposes, schedule piridocaine hydrochloride under HS 29333999. As of Q4 2014, PIRIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piridocaine hydrochloride bears US NLM identifiers UMLS ID C2981293 and NCI Concept Code C87597. SMILES: C1CCC(C(C1)C(=O)OCCC2CCCCN2)N.CL.

UNSPSC 51271920 Piridocaine hydrochloride, a Commodity code, encompasses local anesthetic agents and related pharmaceutical products supplied through cooperative purchasing agreements and multi-state procurement vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively procures generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities. State and local health agencies, correctional systems, and municipal health departments purchase pharmaceutical products under this code through established wholesale channels including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Suppliers must maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), and hold contractual relationships with at least two of the three authorized wholesalers. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.

MMCAP's RFP (S1070000015802), posted January 20, 2026, with response due March 26, 2026, seeks manufacturers to supply comprehensive pharmaceutical products with detailed National Drug Codes (NDC), SKUs, and UPCs across Minnesota and Oregon. Evaluation weights pricing competitiveness at 75 percent, with fixed pricing, net price formats, and WAC-minus options permitted. All products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. MMCAP reserves multi-award authority based on therapeutic considerations, product availability, and patient safety. The contract term is two years for new vendors with optional extensions; incumbents' amendments extend through June 30, 2028. Vendors must comply with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials, and all products must meet FDA requirements with minimum expiration dates of one year from manufacture and six-month shelf life.